JP2011528896A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011528896A5 JP2011528896A5 JP2011519186A JP2011519186A JP2011528896A5 JP 2011528896 A5 JP2011528896 A5 JP 2011528896A5 JP 2011519186 A JP2011519186 A JP 2011519186A JP 2011519186 A JP2011519186 A JP 2011519186A JP 2011528896 A5 JP2011528896 A5 JP 2011528896A5
- Authority
- JP
- Japan
- Prior art keywords
- tuberculosis
- prevention
- protein sequence
- treatment
- rv2386c protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 201000008827 tuberculosis Diseases 0.000 claims 26
- 101100456232 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) mbtI gene Proteins 0.000 claims 24
- 239000003814 drug Substances 0.000 claims 22
- 230000002265 prevention Effects 0.000 claims 22
- 229920001184 polypeptide Polymers 0.000 claims 10
- 102000004196 processed proteins & peptides Human genes 0.000 claims 10
- 108090000765 processed proteins & peptides Proteins 0.000 claims 10
- 230000002163 immunogen Effects 0.000 claims 9
- 239000012634 fragment Substances 0.000 claims 8
- 206010065048 Latent tuberculosis Diseases 0.000 claims 5
- 108091033319 polynucleotide Proteins 0.000 claims 5
- 102000040430 polynucleotide Human genes 0.000 claims 5
- 239000002157 polynucleotide Substances 0.000 claims 5
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 4
- 150000007523 nucleic acids Chemical group 0.000 claims 4
- 230000007420 reactivation Effects 0.000 claims 4
- 230000003111 delayed effect Effects 0.000 claims 2
- 108020001507 fusion proteins Proteins 0.000 claims 2
- 102000037865 fusion proteins Human genes 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 208000036981 active tuberculosis Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000003623 enhancer Substances 0.000 claims 1
- 230000015788 innate immune response Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8369908P | 2008-07-25 | 2008-07-25 | |
| US61/083,699 | 2008-07-25 | ||
| PCT/EP2009/059585 WO2010010179A1 (en) | 2008-07-25 | 2009-07-24 | The tuberculosis rv2386c protein, compositions and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015134587A Division JP6104326B2 (ja) | 2008-07-25 | 2015-07-03 | 結核Ｒｖ２３８６ｃタンパク質、組成物およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011528896A JP2011528896A (ja) | 2011-12-01 |
| JP2011528896A5 true JP2011528896A5 (enExample) | 2012-09-06 |
| JP5981138B2 JP5981138B2 (ja) | 2016-08-31 |
Family
ID=41227131
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011519186A Active JP5981138B2 (ja) | 2008-07-25 | 2009-07-24 | 結核Ｒｖ２３８６ｃタンパク質、組成物およびその使用 |
| JP2015134587A Expired - Fee Related JP6104326B2 (ja) | 2008-07-25 | 2015-07-03 | 結核Ｒｖ２３８６ｃタンパク質、組成物およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015134587A Expired - Fee Related JP6104326B2 (ja) | 2008-07-25 | 2015-07-03 | 結核Ｒｖ２３８６ｃタンパク質、組成物およびその使用 |
Country Status (23)
| Country | Link |
|---|---|
| US (4) | US20110206712A1 (enExample) |
| EP (1) | EP2315834B1 (enExample) |
| JP (2) | JP5981138B2 (enExample) |
| KR (1) | KR20110049834A (enExample) |
| CN (2) | CN102165064B (enExample) |
| AU (1) | AU2009273132B2 (enExample) |
| BR (1) | BRPI0916704A2 (enExample) |
| CA (1) | CA2731547C (enExample) |
| CO (1) | CO6351811A2 (enExample) |
| CY (1) | CY1121632T1 (enExample) |
| DK (1) | DK2315834T3 (enExample) |
| EA (1) | EA201100070A1 (enExample) |
| ES (1) | ES2685498T3 (enExample) |
| HR (1) | HRP20181353T1 (enExample) |
| HU (1) | HUE039159T2 (enExample) |
| IL (1) | IL210589A (enExample) |
| LT (1) | LT2315834T (enExample) |
| MX (1) | MX2011000982A (enExample) |
| PL (1) | PL2315834T3 (enExample) |
| PT (1) | PT2315834T (enExample) |
| SI (1) | SI2315834T1 (enExample) |
| UA (1) | UA107329C2 (enExample) |
| WO (1) | WO2010010179A1 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0708865A8 (pt) * | 2006-03-14 | 2019-01-22 | Univ Oregon Health & Science | métodos para produzir uma resposta imune à tuberculose |
| US20110189217A1 (en) | 2008-06-26 | 2011-08-04 | Barry Michael A | Methods and materials for producing immune responses against polypeptides involved in antibiotic resistance |
| HUE037121T2 (hu) | 2008-07-25 | 2018-08-28 | Glaxosmithkline Biologicals Sa | Új készítmények és eljárások |
| US20110206712A1 (en) * | 2008-07-25 | 2011-08-25 | James Brown | Tuberculosis rv2386c protein, compositions and uses thereof |
| GB201116248D0 (en) | 2011-09-20 | 2011-11-02 | Glaxosmithkline Biolog Sa | Liposome production using isopropanol |
| WO2013090897A1 (en) * | 2011-12-15 | 2013-06-20 | The Trustees Of The University Of Pennsylvania | Using adaptive immunity to detect drug resistance |
| CN104211787A (zh) * | 2013-05-31 | 2014-12-17 | 中国医学科学院病原生物学研究所 | 用于结核病诊断和预防的蛋白 |
| GB201405921D0 (en) * | 2014-04-02 | 2014-05-14 | Glaxosmithkline Biolog Sa | Novel methods for inducing an immune response |
| CN107110862B (zh) * | 2014-08-15 | 2021-03-16 | 牛津免疫科技有限公司 | 结核分枝杆菌蛋白 |
| CN105572352B (zh) * | 2016-02-17 | 2017-07-28 | 遵义医学院附属医院 | 一组结核潜伏感染诊断标志物及其用途 |
| BE1025160B1 (fr) | 2016-12-07 | 2018-11-26 | Glaxosmithkline Biologicals Sa | Nouveau procédé |
| GB201621686D0 (en) | 2016-12-20 | 2017-02-01 | Glaxosmithkline Biologicals Sa | Novel methods for inducing an immune response |
| GB201707700D0 (en) | 2017-05-12 | 2017-06-28 | Glaxosmithkline Biologicals Sa | Dried composition |
| GB2577232B (en) | 2017-05-30 | 2022-07-06 | Glaxosmithkline Biologicals Sa | Novel methods for manufacturing an adjuvant |
| WO2019106192A1 (en) | 2017-12-01 | 2019-06-06 | Glaxosmithkline Biologicals Sa | Saponin purification |
| CN108866213A (zh) * | 2018-06-29 | 2018-11-23 | 周琳 | 结核分枝杆菌利福平耐药性诊断标志物及其应用 |
| CN109234414B (zh) * | 2018-06-29 | 2022-05-17 | 周琳 | 结核分枝杆菌的对氨基水杨酸耐药性诊断标志物及其应用 |
| CN108950031A (zh) * | 2018-06-29 | 2018-12-07 | 周琳 | 结核分枝杆菌的利福平耐药性诊断标志物及其应用 |
| CA3142300C (en) | 2019-06-05 | 2025-02-04 | Glaxosmithkline Biologicals Sa | SAPONIN PURIFICATION |
| BR112021025172A2 (pt) * | 2019-06-14 | 2022-01-25 | Statens Seruminstitut | Proteínas de fusão para vacinas de tuberculose |
| CN112457410B (zh) * | 2020-11-05 | 2023-04-07 | 迈克生物股份有限公司 | 用于结核分枝杆菌感染检测的抗原组合物 |
| DE202022102137U1 (de) | 2022-04-21 | 2022-04-28 | Damayanthi Dalu | Eine neue Zusammensetzung zur Behandlung von Tuberkulose |
| CN115073612B (zh) * | 2022-06-22 | 2024-09-27 | 宁夏大学 | 一种结核分枝杆菌Zera-71cA蛋白纳米颗粒、制备方法及其用途 |
| CN115725607B (zh) * | 2022-07-14 | 2023-11-28 | 山东第一医科大学附属省立医院(山东省立医院) | 一种鼻疽诺卡菌的致病靶基因及其应用 |
| CN120058854A (zh) * | 2025-03-05 | 2025-05-30 | 北京知筹科技有限公司 | 一种调节低密度脂蛋白受体相关蛋白（lrp）的多肽及其应用 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT761231E (pt) | 1992-06-25 | 2000-06-30 | Smithkline Beecham Biolog | Composicao de vacina contendo adjuvantes |
| US6458366B1 (en) | 1995-09-01 | 2002-10-01 | Corixa Corporation | Compounds and methods for diagnosis of tuberculosis |
| US6592877B1 (en) | 1995-09-01 | 2003-07-15 | Corixa Corporation | Compounds and methods for immunotherapy and diagnosis of tuberculosis |
| US6613881B1 (en) | 1997-05-20 | 2003-09-02 | Corixa Corporation | Compounds for immunotherapy and diagnosis of tuberculosis and methods of their use |
| JP4227302B2 (ja) | 1998-04-07 | 2009-02-18 | コリクサ コーポレイション | Ｍｙｃｏｂａｃｔｅｒｉｕｍｔｕｂｅｒｃｕｌｏｓｉｓ抗原の融合タンパク質およびその使用 |
| AU2001241738A1 (en) | 2000-02-25 | 2001-09-03 | Corixa Corporation | Compounds and methods for diagnosis and immunotherapy of tuberculosis |
| JP5139618B2 (ja) | 2000-06-20 | 2013-02-06 | コリクサ コーポレイション | Ｍｙｃｏｂａｃｔｅｒｉｕｍｔｕｂｅｒｃｕｌｏｓｉｓの融合タンパク質 |
| CN1277843C (zh) | 2001-02-22 | 2006-10-04 | 巴斯德研究院 | 分枝杆菌比较基因组学作为鉴定分枝杆菌病的诊断、预防或治疗靶的工具 |
| WO2003070187A2 (en) | 2002-02-15 | 2003-08-28 | Corixa Corporation | Fusion proteins of mycobacterium tuberculosis |
| US20030236393A1 (en) | 2002-03-22 | 2003-12-25 | United States Of America Dept Of Vetrans Affairs | Virulence genes of M. marinum and M. tuberculosis |
| JP2007520718A (ja) | 2004-02-06 | 2007-07-26 | カウンシル オブ サイエンティフィック アンド インダストリアル リサーチ | 治療可能性のあるアドヘシンおよびアドヘシン様タンパク質を同定するためのコンピュータを利用した方法 |
| CA2607715C (en) * | 2005-04-29 | 2015-11-24 | Glaxosmithkline Biologicals S.A. | Novel method for preventing or treating m tuberculosis infection |
| WO2008007942A1 (en) | 2006-07-10 | 2008-01-17 | Het Nederlands Kanker Instituut | Means and methods for manipulating sequential phagolysomal-cytosolic translocation of mycobacteria, and uses thereof |
| EA021391B1 (ru) | 2007-03-02 | 2015-06-30 | Глаксосмитклайн Байолоджикалс С.А. | Способ индукции иммунного ответа, вакцинная композиция, ее применение и набор |
| WO2010010178A1 (en) | 2008-07-25 | 2010-01-28 | Glaxosmithkline Biologicals S.A | The tuberculosis rv2707c protein, compositions and uses thereof |
| CA2731499C (en) | 2008-07-25 | 2017-01-10 | Glaxosmithkline Biologicals S.A. | Composition and use thereof for treating or preventing latent tuberculosis |
| US20110206712A1 (en) * | 2008-07-25 | 2011-08-25 | James Brown | Tuberculosis rv2386c protein, compositions and uses thereof |
| HUE037121T2 (hu) | 2008-07-25 | 2018-08-28 | Glaxosmithkline Biologicals Sa | Új készítmények és eljárások |
| JP5839361B2 (ja) | 2009-04-24 | 2016-01-06 | スタテンス セールム インスティトゥート | 再活性化を予防する結核ｔｂワクチン |
| US8367055B2 (en) | 2009-05-14 | 2013-02-05 | Wisconsin Alumni Research Foundation | Immunogenic compositions against tuberculosis |
| HUE031184T2 (en) | 2010-01-27 | 2017-06-28 | Glaxosmithkline Biologicals Sa | Modified tuberculosis antigens |
-
2009
- 2009-07-24 US US13/055,787 patent/US20110206712A1/en not_active Abandoned
- 2009-07-24 CN CN200980138405.9A patent/CN102165064B/zh active Active
- 2009-07-24 JP JP2011519186A patent/JP5981138B2/ja active Active
- 2009-07-24 DK DK09781057.6T patent/DK2315834T3/en active
- 2009-07-24 HR HRP20181353TT patent/HRP20181353T1/hr unknown
- 2009-07-24 EP EP09781057.6A patent/EP2315834B1/en active Active
- 2009-07-24 WO PCT/EP2009/059585 patent/WO2010010179A1/en not_active Ceased
- 2009-07-24 ES ES09781057.6T patent/ES2685498T3/es active Active
- 2009-07-24 EA EA201100070A patent/EA201100070A1/ru unknown
- 2009-07-24 AU AU2009273132A patent/AU2009273132B2/en not_active Ceased
- 2009-07-24 HU HUE09781057A patent/HUE039159T2/hu unknown
- 2009-07-24 KR KR1020117004639A patent/KR20110049834A/ko not_active Ceased
- 2009-07-24 PL PL09781057T patent/PL2315834T3/pl unknown
- 2009-07-24 CA CA2731547A patent/CA2731547C/en active Active
- 2009-07-24 CN CN201710068231.XA patent/CN106866801A/zh active Pending
- 2009-07-24 PT PT97810576T patent/PT2315834T/pt unknown
- 2009-07-24 MX MX2011000982A patent/MX2011000982A/es active IP Right Grant
- 2009-07-24 BR BRPI0916704-8A patent/BRPI0916704A2/pt not_active IP Right Cessation
- 2009-07-24 SI SI200931869T patent/SI2315834T1/sl unknown
- 2009-07-24 UA UAA201100300A patent/UA107329C2/uk unknown
- 2009-07-24 LT LTEP09781057.6T patent/LT2315834T/lt unknown
-
2011
- 2011-01-12 IL IL210589A patent/IL210589A/en not_active IP Right Cessation
- 2011-01-27 CO CO11009237A patent/CO6351811A2/es not_active Application Discontinuation
-
2013
- 2013-06-27 US US13/929,232 patent/US20140086948A1/en not_active Abandoned
-
2014
- 2014-05-21 US US14/283,727 patent/US9480735B2/en active Active
-
2015
- 2015-07-03 JP JP2015134587A patent/JP6104326B2/ja not_active Expired - Fee Related
-
2016
- 2016-09-15 US US15/266,220 patent/US10286053B2/en active Active
-
2018
- 2018-08-24 CY CY20181100883T patent/CY1121632T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011528896A5 (enExample) | ||
| JP2011528895A5 (enExample) | ||
| JP2011528897A5 (enExample) | ||
| JP2012126742A5 (enExample) | ||
| JP2012136541A5 (enExample) | ||
| JP2013172734A5 (enExample) | ||
| JP2013231081A5 (enExample) | ||
| HRP20161458T1 (hr) | Polipeptidi, polinukleotidi i pripravci namijenjeni upotrebi u liječenju latentne tuberkuloze | |
| CA2818990C (en) | Designed repeat proteins binding to serum albumin | |
| JP2009268467A5 (enExample) | ||
| JP2011136997A5 (enExample) | ||
| JP2012115277A5 (enExample) | ||
| JP2014051497A5 (enExample) | ||
| JP2014507144A5 (ja) | 慢性ｂ型肝炎感染症のための酵母系免疫療法組成物 | |
| JP2008536483A5 (enExample) | ||
| FI3581650T3 (fi) | IX-tekijän polypeptidimutantti, sen käyttöjä ja menetelmä sen valmistamiseksi | |
| JP2008508859A5 (enExample) | ||
| JP2008530245A5 (enExample) | ||
| JP2010534684A5 (enExample) | ||
| JP2015096557A5 (enExample) | ||
| JP2009213477A5 (enExample) | ||
| JP2015510393A5 (enExample) | ||
| JP2010503396A5 (enExample) | ||
| JP2015517489A5 (enExample) | ||
| JP2014529399A5 (enExample) |